A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. 

 -  2022 
<br/><br/> While rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA. Copyright © 2022, Rao et al. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2168-8184 
<br/><br/><label>Standard No.: </label>10.7759/cureus.30106 [doi] PMC9643074 [pmc] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>IN PROCESS -- NOT YET INDEXED
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Union Memorial Hospital
<br/><br/><label>Index Terms--Occupation: </label><br/>Internal Medicine<br/>Internal Medicine Residency
<br/><br/><label>Index Terms--Function: </label><br/>Case Reports